ν˜„λŒ€ADM 둜고

ν˜„λŒ€ADM (187660) μ£Όκ°€ 및 μ’…λͺ© 정보

ν˜„λŒ€ADM μ‹€μ‹œκ°„ μ£Όκ°€

ν˜„λŒ€ADM ν˜„μž¬κ°€ 상세 정보
ν•­λͺ© κ°’
ν˜„μž¬κ°€ 2,465 원
λ³€λ™λŸ‰ β–² 45.00 원
변동λ₯  1.86%
κ±°λž˜λŸ‰ 636,149
κ±°λž˜λŒ€κΈˆ 1,567,244,659 원

ν˜„λŒ€ADM 일별 μ£Όκ°€

ν˜„λŒ€ADM의 κ³Όκ±° 일별 μ£Όκ°€
λ‚ μ§œ μ‹œκ°€ κ³ κ°€ μ €κ°€ μ’…κ°€ κ±°λž˜λŸ‰ κ±°λž˜λŒ€κΈˆ
11/16/2025 3,000 3,030 2,860 2,920 1,259,705 3,694,050,381
11/17/2025 2,870 2,905 2,695 2,695 1,237,729 3,438,330,499
11/18/2025 2,720 2,740 2,610 2,625 871,641 2,309,343,008
11/19/2025 2,625 2,720 2,550 2,570 847,976 2,219,730,151
11/20/2025 2,490 2,530 2,390 2,465 753,009 1,860,579,996
11/23/2025 2,490 2,530 2,395 2,440 709,844 1,737,711,227
11/24/2025 2,480 2,500 2,355 2,415 703,234 1,698,290,669
11/25/2025 2,420 2,470 2,410 2,445 445,622 1,085,548,134
11/26/2025 2,455 2,510 2,385 2,420 553,378 1,342,101,307
11/27/2025 2,440 2,490 2,420 2,465 636,149 1,567,244,659

κ΄€λ ¨ ν…Œλ§ˆ

ν˜„λŒ€ADM νšŒμ‚¬ 정보

μ‹œμž₯ μ‹œκ°€μ΄μ•‘ κΈ°μ—…μˆœμœ„ μ£Όμ‹μˆ˜ 외ꡭ인 비쀑 μ‚°μ—…κ΅° μ„ΈλΆ€ μ‚°μ—…κ΅° 52μ£Ό 졜고 52μ£Ό μ΅œμ €
kosdaq 1,332μ–΅ 630μœ„ 54,075,422 0.62% ν—¬μŠ€μΌ€μ–΄ 생λͺ…κ³Όν•™/곡학 3,795 1,118

ν˜„λŒ€ADM κΈ°μ—… κ°œμš”

μ—μ΄λ””μ— μ½”λ¦¬μ•„λŠ” 2003λ…„ 10μ›” μ„€λ¦½λœ κΈ°μ—…μœΌλ‘œ μž„μƒμ‹œν—˜ μˆ˜νƒκΈ°κ΄€μœΌλ‘œ μ œμ•½νšŒμ‚¬, λ°”μ΄μ˜€λ²€μ²˜ 등에 μž„μƒμ‹œν—˜κ³Ό κ΄€λ ¨ν•œ μ „ μ˜μ—­μ— 걸친 μ„œλΉ„μŠ€ 사업을 μ˜μœ„ν•˜κ³  μžˆλ‹€. μ£Όμš” 쒅속기업은 μ—μ΄λ””μ— λ°”μ΄μ˜€μ‚¬μ΄μ–ΈμŠ€(μ£Ό)κ°€ μžˆλ‹€. μ£Όμš” λ§€μΆœμ€ μš©μ—­ λΆ€λ¬Έμ—μ„œ λ°œμƒν•˜κ³  μžˆλ‹€. μ‹ μ•½μ˜ μ‹œνŒμ„ μœ„ν•΄μ„œλŠ” μž‘κ²ŒλŠ” 5λ…„μ—μ„œ 평균 10λ…„ λ™μ•ˆ 단계별 μž„μƒμ‹œν—˜(1상, 2상, 3상)을 μˆ˜ν–‰ν•΄μ•Ό ν•˜λ©°, λ‹Ήμ‚¬λŠ” μ΄λŸ¬ν•œ 역할을 μˆ˜ν–‰ν•˜κΈ° μœ„ν•΄ κ³ κ°μ‚¬λ‘œλΆ€ν„° μž„μƒμ‹œν—˜μ— κ΄€ν•œ 전체 λ˜λŠ” 일뢀 업무λ₯Ό μœ„νƒ λ°›μ•„ μˆ˜ν–‰ν•˜κ³  μžˆλ‹€.

μ΅œμ‹  ν˜„λŒ€ADM κ΄€λ ¨ λ‰΄μŠ€

[μΈν¬μŠ€νƒλ°μΌλ¦¬=박상철 기자]β–  美 FOMC μ˜μ‚¬λ‘ 곡개 - ν˜„μ§€μ‹œκ°„ 19일(ν•œκ΅­μ‹œκ°„ 20일 μ˜€μ „ 4μ‹œ) λ―Έκ΅­ μ—°λ°©κ³΅κ°œμ‹œμž₯μœ„μ›νšŒ(FOMC)의 10μ›” μ˜μ‚¬λ‘μ΄ 곡개될 μ˜ˆμ •μ΄λ‹€.β–  美 μ—”λΉ„λ””μ•„ μ‹€μ λ°œν‘œ - ν˜„μ§€μ‹œκ°„ 19일(ν•œκ΅­μ‹œκ°„ 20일 μ˜€μ „ 7μ‹œ) 컴퓨터 κ·Έλž˜ν”½μš© μΉ© μ œμ‘°μ—…μ²΄μΈ μ—”λΉ„λ””μ•„(NVIDIA)κ°€ 3λΆ„κΈ° 싀적을 λ°œν‘œν•œλ‹€. κ΄€λ ¨ μ„Ήν„°λ‘œλŠ” λ°˜λ„μ²΄ λŒ€ν‘œμ£Ό(생산), λ°˜λ„μ²΄ μž₯λΉ„, λ°˜λ„μ²΄ 재료/λΆ€ν’ˆ, μ‹œμŠ€ν…œλ°˜λ„μ²΄, IT λŒ€ν‘œμ£Ό, HBM(κ³ λŒ€μ—­ν­λ©”λͺ¨λ¦¬)이 μžˆλ‹€.β–  μ‘΄ μœŒλ¦¬μ—„μŠ€ λ‰΄μš• 연은 총재 μ—°μ„€ - ν˜„μ§€μ‹œκ°„ 19일 μ‘΄ μœŒλ¦¬μ—„μŠ€ λ‰΄μš• μ—°λ°©

ν˜„λŒ€ADM은 μž„μƒ μ „λ¬ΈκΈ°κ΄€ ν”„λ¦¬ν΄λ¦¬λ‚˜μ—κ²Œ μ•žμ„œ μ§„ν–‰ν•œ λΉ„μž„μƒ μ •λ°€ 뢄석 의뒰결과 κΈ°μ‘΄ λ©΄μ—­μ–΅μ œ μΉ˜λ£Œμ™€ 달리 λ₯˜λ§ˆν‹°μŠ€ κ΄€μ ˆμ—Όμ˜ 근본적 원인인 '병리적 쑰직'을 μ •μƒν™”μ‹œν‚¨ κ²ƒμœΌλ‘œ λ³΄μ΄λŠ” 데이터λ₯Ό ν™•μΈν–ˆλ‹€κ³  14일 λ°ν˜”λ‹€. νšŒμ‚¬λŠ” μ•žμ„œ μ§„ν–‰ν•œ λΉ„μž„μƒμ‹œν—˜ λŒ€μƒ 각ꡰ별 μ₯λ“€μ— λŒ€ν•œ μ •λ°€ν•œ 쑰직뢄석을 μ˜λ’°ν•΄ 이 같은 κ²°κ³Όλ₯Ό μ–»μ—ˆλ‹€κ³  μ„€λͺ…ν–ˆλ‹€. 쑰직뢄석 결과에 λ”°λ₯΄λ©΄ λŒ€μ‘°κ΅°(무처치ꡰ)은 병리적 쑰직(pannus)이 ν˜•μ„±λ˜μ–΄ '연골-골 경계'κ°€ λΆ•κ΄΄λμœΌλ©° 염증세포도 κ΄‘λ²”μœ„ν•˜κ²Œ μ‘΄μž¬ν•œ κ²ƒμœΌλ‘œ ν™•μΈν–ˆλ‹€. ν˜„μž¬ ν‘œμ€€ 치료제인 MTX νˆ¬μ—¬κ΅°μ—μ„œλŠ” 염증 μ–΅μ œλŠ” μ΄λ£¨μ–΄μ‘Œμ§€λ§Œ 병리적 쑰직은 μ—¬μ „νžˆ μœ μ§€λλ‹€. 반면 ν˜„λŒ€ADM의 νŽ˜λ‹ˆνŠΈλ¦¬μ›€(Penetrium) 단독 νˆ¬μ—¬κ΅°μ€ 병리적 쑰직이 91% 이상 μ€„μ–΄λ“€μ—ˆκ³  이둜 인해 염증도 ν˜„μ €νžˆ κ°μ†Œν•œ κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. νŽ˜λ‹ˆνŠΈλ¦¬μ›€κ³Ό κΈ°μ‘΄ 치료제인 MTXλ₯Ό ν•¨κ»˜ νˆ¬μ•½ν•œ λ³‘μš©κ΅°μ€ 병리적 쑰직이 98% 이상 μ€„μ—ˆκ³  염증도 사라져 μ™„μ „κ΄€ν•΄ μˆ˜μ€€μ˜ 쑰직 정상화λ₯Ό κ΄€μ°°ν–ˆλ‹€. ν˜„λŒ€AD...

[μΈν¬μŠ€νƒλ°μΌλ¦¬=박상철 기자]β–  λ―Έκ΅­ μ±„κΆŒμ‹œμž₯ 휴μž₯ - ν˜„μ§€μ‹œκ°„ 11일 λ‰΄μš• μ±„κΆŒμ‹œμž₯은 재ν–₯ꡰ인의 λ‚ λ‘œ 휴μž₯ν•  μ˜ˆμ •μ΄λ‹€. λ―Έκ΅­ μ£Όμ‹μ‹œμž₯은 정상 κ±°λž˜ν•œλ‹€.β–  쀑ꡭ κ΄‘κ΅°μ œ - μ€‘κ΅­μ˜ μ΅œλŒ€ 할인 행사인 '11Β·11 μ‡Όν•‘ μΆ•μ œ(κ΄‘κ΅°μ œ)'κ°€ 11μ›” 11일에 개졜될 μ˜ˆμ •μ΄λ‹€. κ΄€λ ¨ μ„Ήν„°λ‘œλŠ” μ†Œλ§€μœ ν†΅, ν™”μž₯ν’ˆμ΄ μžˆλ‹€.β–  ꡭ무회의 개졜 - 11μ›” 11일 κ΅­λ¬΄νšŒμ˜κ°€ 개졜될 μ˜ˆμ •μ΄λ©°, 2035λ…„ κ΅­κ°€μ˜¨μ‹€κ°€μŠ€ 감좕λͺ©ν‘œ(NDC)κ°€ μ΅œμ’… 의결될 μ˜ˆμ •μ΄λ‹€. κ΄€λ ¨ μ„Ήν„°λ‘œλŠ” μ˜¨μ‹€κ°€μŠ€(νƒ„μ†Œλ°°μΆœκΆŒ)/νƒ„μ†Œ ν¬μ§‘Β·ν™œμš©Β·μ €μž₯(CCUS)이 μžˆλ‹€.β–  μ •λΆ€,

ν˜„λŒ€ADMλ°”μ΄μ˜€κ°€ 10μ›” 23일(ν˜„μ§€μ‹œκ°„) λͺ¨νšŒμ‚¬ ν˜„λŒ€λ°”μ΄μ˜€μ‚¬μ΄μ–ΈμŠ€μ™€ ν•¨κ»˜ 美 λ³΄μŠ€ν„΄μ—μ„œ 열리고 μžˆλŠ” 'AACR-NCI-EORTC 2025' κ΅­μ œν•™νšŒμ—μ„œ λ°œν‘œν•œ νŽ˜λ‹ˆνŠΈλ¦¬μ›€(Penetrium)의 μžκ°€λ©΄μ—­μ§ˆν™˜ μ „μž„μƒ 쀑간 연ꡬ κ²°κ³Όλ₯Ό νšŒμ‚¬ ν™ˆνŽ˜μ΄μ§€ 곡지문을 톡해 24일 κ³΅κ°œν–ˆλ‹€. 이번 κ²°κ³ΌλŠ” μ§€λ‚œ 14일 μ„œμšΈ ν”„λ ˆμŠ€μ„Όν„°μ—μ„œ 곡개된 λ₯˜λ§ˆν‹°μŠ€ κ΄€μ ˆμ—Ό 및 λ‹€λ°œμ„± 경화증 연ꡬ에 이어, 건선과 크둠병 μΆ”κ°€ 연ꡬλ₯Ό ν¬ν•¨ν•œ 후속 결과둜, 4개 λŒ€ν‘œ μ§ˆν™˜ λͺ¨λ‘μ—μ„œ 동일 약물·동일 μš©λŸ‰Β·λ™μΌ νˆ¬μ•½λ²•μœΌλ‘œ μΌκ΄€λœ 효

ν˜„λŒ€ADMλ°”μ΄μ˜€λŠ” λͺ¨νšŒμ‚¬ ν˜„λŒ€λ°”μ΄μ˜€μ‚¬μ΄μ–ΈμŠ€μ™€ ν•¨κ»˜ λ―Έκ΅­ λ³΄μŠ€ν„΄μ—μ„œ 열리고 μžˆλŠ” 'AACR-NCI-EORTC 2025' κ΅­μ œν•™νšŒμ—μ„œ λ°œν‘œν•œ νŽ˜λ‹ˆνŠΈλ¦¬μ›€(Penetrium)의 μžκ°€λ©΄μ—­μ§ˆν™˜ μ „μž„μƒ 쀑간 연ꡬ κ²°κ³Όλ₯Ό νšŒμ‚¬ ν™ˆνŽ˜μ΄μ§€ 곡지문을 톡해 24일 κ³΅κ°œν–ˆλ‹€.AACR-NCI-EORTCλŠ” λ―Έκ΅­μ•”ν•™νšŒ(AACR), λ―Έκ΅­κ΅­λ¦½μ•”μ—°κ΅¬μ†Œ(NCI) 및 μœ λŸ½μ•”μ—°κ΅¬μΉ˜λ£ŒκΈ°κ΅¬(EORTC)κ°€ 곡동 μ£Όμ΅œν•˜λŠ” κΈ€λ‘œλ²Œ ν•™μˆ λŒ€νšŒλ‹€. 이번 κ²°κ³ΌλŠ” μ§€λ‚œ 14일 μ„œμšΈ ν”„λ ˆμŠ€μ„Όν„°μ—μ„œ 곡개된 λ₯˜λ§ˆν‹°μŠ€

ν˜„λŒ€ADM 맀좜 정보

λ‚ μ§œ λ§€μΆœμ•‘ λ§€μΆœμ•‘ μ¦κ°€μœ¨ μ˜μ—…μ΄μ΅ μ˜μ—…μ΄μ΅ μ¦κ°€μœ¨ 순이읡 순이읡 μ¦κ°€μœ¨
2024.4Q 9,744,986,676 -29.33% -15,932,446,161 -359.86% -20,260,475,756 -502.40%
2023.4Q 13,790,195,699 -7.34% -3,464,613,885 -359.05% -3,363,294,388 -5611.85%
2022.4Q 14,882,556,000 6.47% -754,740,500 -136.10% -58,882,744 -103.41%
2021.4Q 13,977,772,000 - 2,090,550,500 - 1,726,994,300 -

μˆœλ§€μˆ˜λŸ‰

개인: 2,835

κΈ°κ΄€: 0

외인: 165

λˆ„μ  μˆœλ§€μˆ˜λŸ‰

개인: 2,458,963

κΈ°κ΄€: -1,604,636

외인: -355,253

순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2025-11-28 2,835 - 165
2025-11-27 112,732 - -107,732
2025-11-26 9,151 - -4,151
2025-11-25 -20,593 - 54,277
2025-11-24 -52,600 - 88,851
2025-11-21 -12,441 - 42,971
2025-11-20 74,696 - -36,743
2025-11-19 -107,141 - 126,949
2025-11-18 -26,918 - 28,576
2025-11-17 -68,237 - 68,237
2025-11-14 174,645 - -196,683
2025-11-13 134,418 - 156,082
2025-11-12 469,827 - -398,025
2025-11-11 -230,869 - 208,098
2025-11-10 -59,846 -10,000 67,246
2025-11-07 -78,463 - 54,311
2025-11-06 -92,277 - 85,517
2025-11-05 157,373 - -158,373
2025-11-04 171,135 - -131,135
2025-11-03 -257,007 - 221,155
2025-10-31 -15,394 - 15,394

λˆ„μ  순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2025-11-28 285,026 -10,000 184,987
2025-11-27 282,191 -10,000 184,822
2025-11-26 169,459 -10,000 292,554
2025-11-25 160,308 -10,000 296,705
2025-11-24 180,901 -10,000 242,428
2025-11-21 233,501 -10,000 153,577
2025-11-20 245,942 -10,000 110,606
2025-11-19 171,246 -10,000 147,349
2025-11-18 278,387 -10,000 20,400
2025-11-17 305,305 -10,000 -8,176
2025-11-14 373,542 -10,000 -76,413
2025-11-13 198,897 -10,000 120,270
2025-11-12 64,479 -10,000 -35,812
2025-11-11 -405,348 -10,000 362,213
2025-11-10 -174,479 -10,000 154,115
2025-11-07 -114,633 - 86,869
2025-11-06 -36,170 - 32,558
2025-11-05 56,107 - -52,959
2025-11-04 -101,266 - 105,414
2025-11-03 -272,401 - 236,549
2025-10-31 -15,394 - 15,394

ν˜„λŒ€ADM μžμ‚° λΉ„μœ¨

μžμ‚°μ΄κ³„ λΆ€μ±„λΉ„μœ¨ μžλ³ΈλΉ„μœ¨
25,538,658,728 57.96% 42.04%

ν˜„λŒ€ADM 맀좜 ꡬ성

ꡬ성 μš”μ†Œ λΉ„μœ¨
Clinical trial [μš©μ—­] 64.9%
LPS [μš©μ—­] 32.9%
μž„λŒ€ 1.9%
μƒν’ˆ [μž¬ν™”μ˜] 0.3%

ν˜„λŒ€ADM 곡맀도 ν˜„ν™©

졜근 곡맀도 κ±°λž˜λŸ‰: 103 (0.02%)

졜근 곡맀도 μž”κ³ : 346,292 (0.64%)

곡맀도 κ±°λž˜λŸ‰

λ‚ μ§œ μ’…κ°€ κ³΅λ§€λ„λŸ‰ 곡맀도비쀑
2025-11-28 2,465 103 0.02%
2025-11-27 2,420 114 0.02%
2025-11-26 2,445 0 0.00%
2025-11-25 2,415 0 0.00%
2025-11-24 2,440 0 0.00%
2025-11-21 2,465 0 0.00%
2025-11-20 2,570 0 0.00%
2025-11-19 2,625 0 0.00%
2025-11-18 2,695 0 0.00%
2025-11-17 2,920 325 0.03%
2025-11-14 2,970 32 0.00%
2025-11-13 2,945 104 0.00%
2025-11-12 2,840 316 0.01%
2025-11-11 2,895 2,079 0.05%
2025-11-10 2,640 13,319 1.90%
2025-11-07 2,590 2,460 0.21%
2025-11-06 2,740 1 0.00%
2025-11-05 2,780 1,058 0.05%
2025-11-04 2,740 4,917 0.24%
2025-11-03 2,740 580 0.04%
2025-10-31 2,840 86 0.01%

곡맀도 μž”κ³ 

λ‚ μ§œ μ’…κ°€ 곡맀도 μž”κ³  곡맀도 비쀑
2025-11-26 2,445 346,292 0.64%
2025-11-25 2,415 317,684 0.59%
2025-11-24 2,440 290,843 0.54%
2025-11-21 2,465 354,637 0.66%
2025-11-20 2,570 295,172 0.55%
2025-11-19 2,625 312,205 0.58%
2025-11-18 2,695 371,553 0.70%
2025-11-17 2,920 373,705 0.71%
2025-11-14 2,970 389,447 0.74%
2025-11-13 2,945 259,568 0.49%
2025-11-12 2,840 353,358 0.67%
2025-11-11 2,895 225,321 0.43%
2025-11-10 2,640 225,321 0.44%
2025-11-07 2,590 222,857 0.44%
2025-11-06 2,740 309,466 0.61%
2025-11-05 2,780 374,867 0.74%
2025-11-04 2,740 309,737 0.61%
2025-11-03 2,740 210,650 0.41%
2025-10-31 2,840 345,834 0.68%
2025-10-30 2,830 359,883 0.71%
2025-10-29 2,910 382,809 0.75%

ν˜„λŒ€ADM μ—…μ’… λ‚΄ 비ꡐ

생λͺ…κ³Όν•™/곡학 μ—…μ’…(90개) μ—°κ°„ κΈ°μ€€

ν•­λͺ© ν˜„λŒ€ADM μ—…μ’… 평균 μ—…μ’… λ‚΄ μˆœμœ„
μ‹œκ°€μ΄μ•‘ 1,308.625 10,775.37 48μœ„
PER(졜근4λΆ„κΈ°) -8.384 -156.93 55μœ„
PBR 11.283 24.89 23μœ„
ROE(졜근4λΆ„κΈ°) -118.306 -33.48 83μœ„
λ°°λ‹Ήμˆ˜μ΅λ₯ (μ΅œκ·Όμ—°λ„) - - -μœ„
μ˜μ—…μ΄μ΅λ₯ (μ΅œκ·Όμ—°λ„) -163.494 -1,637.76 46μœ„
순이읡λ₯ (μ΅œκ·Όμ—°λ„) -207.907 -1,546.74 54μœ„
λΆ€μ±„λΉ„μœ¨(μ΅œκ·Όμ—°λ„) 330.363 77.86 2μœ„
λ§€μΆœμ•‘(μ΅œκ·Όμ—°λ„) 97.45 490.15 40μœ„
μ˜μ—…μ΄μ΅(μ΅œκ·Όμ—°λ„) -159.324 -86.02 64μœ„
λ‹ΉκΈ°μˆœμ΄μ΅(μ΅œκ·Όμ—°λ„) -202.605 -64.08 71μœ„